BMY
BMY
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
3
$412K
Insider Sales
6
$4.96M
Total Volume
$5.37M
9 transactions
Net Activity
$4.55M
Net selling
Sentiment Rating
Moderate AccumulationCEO Conviction Index
High Conviction Accumulation
Key Drivers
- •Heavy distribution: sales represent 92% of total transaction value.
- •Minor cluster buying: 2 unique insiders purchased shares.
- •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Elkins David V
EVP, CFO
$4.50M total
Massacesi Cristian
EVP,Chief Med Offr,Head of Dev
$403K total
Hirawat Samit
EVP,Chief Med.Offr.,Drug Dev.
$302K total
Boerner Christopher S.
CEO
$110K total
Holzer Phil M
SVP, Controller
$34K total
Quick Actions
BMY has an insider buy conviction of 8%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at BMY (BMY) engaged in a total of 9 transactions reported via SEC Form 4 filings. Among these, 3 were open-market purchases and 6 were sales. The total volume of insider trading reached $5.37M.
The net insider activity for BMY shows a net selling bias of $4.55M. This activity represents a 8% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Elkins David V (EVP, CFO), who traded 56.0K shares valued at $2.65M on Sep 2, 2025.
Is Bristol-Myers Squibb (BMY) Fully Valued Following Its Hematology Data Update?
Bristol-Myers Squibb (NYSE:BMY): Dividend Quality Screen Highlights Income Case and Sustainability Risk
Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival Crashes
Which Dates Could Move Bristol Myers Squibb Stock Most?
Our Bristol Myers Squibb Stock Pick Is Up 35%. It’s Still a Good Bet in Healthcare.
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors
FAQs About BMY Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for BMY.